SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-2709"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-2709" > Current Medical Tre...

Current Medical Treatment of Endocrine Pancreatic Tumors and Future Aspects

Fjällskog, Marie-Louise, (författare)
Uppsala universitet, Institutionen för medicinska vetenskaper
Vatn, Morten, Ph.D (opponent)
Med avd Gastro, Rikshospitalet, Oslo
ISBN 91-554-5424-0
Uppsala : Acta Universitatis Upsaliensis, 2002
Engelska 71s.
Serie: Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, 0282-7476
  • Doktorsavhandling (övrigt vetenskapligt)
Abstract Ämnesord
Stäng  
  • <p>We treated 16 patients with somatostatin analogs combined with α-interferon and achieved a biochemical and/or radiological response in 56% (median duration 22 months). We consider this treatment a good alternative for patients who fail during chemotherapy or who do not want to/cannot receive cytotoxic drugs.</p><p>Thirty-six patients with neuroendocrine tumors were treated with cisplatin combined with etoposide. Of 14 patients with evaluable EPTs, 50% responded radiologically and/or biochemically (median duration 9 months). We consider this treatment useful as first-line medical treatment in aggressive EPTs or in patients failing prior chemotherapy.</p><p>Twenty-eight tumor tissues from EPTs were examined with immunohistochemistry regarding expression of somatostatin receptors (ssts) 1 to 5 on tumor cells and in intratumoral vessels. We found that sst<sub>2</sub> and sst<sub>4</sub> were highly expressed on tumor cells and in vessels. However, sst<sub>3</sub> and sst<sub>5</sub> were lacking in half of the tumor tissues and in most of the vessels. Because of the variability in sst expression, we recommend analysis of each individual’s receptor expression before starting treatment.</p><p>Endocrine pancreatic tumors (EPTs) are rare with an incidence of 4 per million inhabitants. In the majority of cases they grow slowly, but there are exceptions with very rapidly progressing malignant carcinomas. First-line medical treatment is streptozotocin combined with 5-fluorouracil.</p><p>We examined 38 tumor samples regarding expression of tyrosine kinase receptors platelet-derived growth factor receptors (PDGFRs), c-kit and epidermal growth factor receptor (EGFR). We found that the receptors were expressed in more than half of the tumor tissues. Further studies will reveal if tyrosin kinase antagonists can be part of the future treatment arsenal.</p>

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  (hsv//swe)
MEDICAL AND HEALTH SCIENCES  (hsv//eng)

Nyckelord

Medical sciences
pancreatic tumors
somatostatin analogs
cisplatin
etoposide
somatostatin receptors
immunohistochemistry
tyrosine kinase receptors
platelet-derived growth factors receptors (PDGFRs)
c-kit
epidermal growth factor receptor (EGFR)
MEDICIN OCH VÅRD
alfa-interferon
MEDICINE
MEDICIN
Medicine
medicin

Publikations- och innehållstyp

vet (ämneskategori)
dok (ämneskategori)
vet (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy